Outlet metrics
Global
#636354
United States
#201979
Health/Biotechnology and Pharmaceuticals
#169
Articles
-
6 days ago |
oncologypipeline.com | Madeleine Armstrong
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet. AstraZeneca and Daiichi Sankyo’s HER2-targeting ADC Enhertu, which made $3.8bn in 2024, could soon be heading for first-line breast cancer, following positive data presented at ASCO on Monday from the Destiny-Breast09 trial. The study, in HER2-positive disease, found a 44% reduction in the risk of progression or death with Enhertu plus Roche’s Perjeta, versus Perjeta plus Herceptin and chemo.
-
1 week ago |
oncologypipeline.com | Madeleine Armstrong
But camizestrant’s use could depend on uptake of monitoring – for now. AstraZeneca, seeking an earlier use for its oral SERD camizestrant, told ASCO on Sunday how a new paradigm of treating patients who develop the ESR1 mutation during first-line therapy but before progression improves not only progression-free survival but also PFS2, a more relevant real-world endpoint. However, the real test will be overall survival, and these data are still immature.
-
1 week ago |
oncologypipeline.com | Madeleine Armstrong
BioNTech’s DualityBio-originated B7-H3-targeting ADC BNT324 could have a new use, castrate-resistant prostate cancer, although the company is being cautious about taking this indication forward. Late-line mCRPC cohorts from a phase 1 solid tumour trial, reported at ASCO on Sunday, found a confirmed ORR of 31% across two doses – which looks favourable versus other early-stage prostate cancer assets in development, including J&J’s anti-KLK2 T-cell engager pasritamig, presented at the same session.
-
1 week ago |
oncologypipeline.com | Madeleine Armstrong
The company highlights the safety of its KLK2-targeting T-cell engager pasritamig. At last year’s ASCO Johnson & Johnson saw troubling toxicity with a KLK2-targeting radiopharmaceutical project; this year the group moved to showcase a different asset that it believes to be much safer, the anti-KLK2 T-cell engager pasritamig.
-
1 week ago |
oncologypipeline.com | Madeleine Armstrong
In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo. Earlier this year Exelixis’s next-generation tyrosine kinase inhibitor zanzalintinib disappointed in colorectal cancer, but now it has shown more promise in first-line renal cancer, ASCO heard on Saturday. Notably, on a cross-trial basis the asset looks more efficacious than Exelixis’s approved TKI Cabometyx, with lower toxicity.
ApexOnco journalists
Contact details
Address
123 Example Street
City, Country 12345
Email Patterns
Contact Forms
Contact Form
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →